The challenges in the treatment of systemic fungal infections after HSCT include: (1) changing epidemiology as less drug-susceptible saprophytic fungi are increasingly associated with human disease; (2) the difficulty of early and correct diagnosis, even with the new generation of enzymatic immunoassays; (3) the inability to reduce or eliminate predisposing factors, especially severe immune suppression in most transplant patients with these infections and (4) the uncertain role of antifungal drug combinations and risk of drug antagonism complicating effective empiric-pre-emptive therapy. Current, developing and future immune enhancement strategies including recombinant granulocyte-and granulocyte macrophagecolony stimulating factor (GM-CSF), interferon-gamma (IFN-c), adjuvant pro-inflammatory cytokine therapy during mobilized donor granulocyte transfusions, therapeutic potential of pentraxin, adaptive immune transfer and dendritic cell fungal vaccines. Improved understanding of the molecular pathogenesis of fungal infections and of the complexity of host antifungal immune responses has provided the critical information to readdress existing treatment paradigms and further evaluate the role of GM-CSF and IFN-c early in the course of therapy against lifethreatening fungal infections in high-risk patients following stem cell transplantation.
Introduction
In patients with hematologic malignancies who undergo HSCT, invasive fungal infections (IFI) are a prominent cause of morbidity and death. 1 Even in the present era of highly active anti-Aspergillus drugs such as voriconazole and caspofungin, the response to treatment in patients with severe neutropenia after HSCT remains mostly unfavorable. 2, 3 Amelioration of the underlying predisposing conditions is important in achieving a favorable response to antifungal drug therapy. 4 For example, persistent granulocytopenia due to myeloablative preparatory therapy occurs before engraftment, or results from graft failure, or relapsed cancer, severely compromising the outcome of drug therapy. 5 Late post-transplant fungal infections are commonly noted in patients receiving treatment for GVHD; in these non-neutropenic patients, a favorable response to antifungal treatment requires reduction or, when possible, discontinuation of drug-induced immune suppression. 6 During the post-transplant period, immunosuppressive viral infections (e.g. CMV infection) may also increase the risk of secondary opportunistic bacterial and fungal infections. 7 In this article, I will review the changing spectrum of IFI after HSCT, the limitations of the new generation of diagnostic tests, and the limited response of IFI to systemic antifungal drug therapy alone and then explore emerging and re-emerging immune enhancement strategies to improve the response to antifungal therapy.
Changing epidemiology
The decline in systemic yeast infections in the past decade has been attributed mostly to the common use of fluconazole or itraconazole prophylaxis in patients undergoing HSCT. [8] [9] [10] Such prophylaxis benefits granulocytopenic patients during the early post-transplantation period, and even non-neutropenic patients with GVHD have benefited from anti-Candida prophylaxis during the late post-transplantation phase. 11 Despite the increase in difficult-to-treat Candida glabrata and Candida krusei breakthrough infections, triazoles prophylaxis during the high-risk periods has been viewed favorably, as the overall incidence of systemic candidiasis has diminished considerably in the past decade. 8, 11 Infections due to filamentous moulds, on the other hand, have increased, and furthermore, this rise in part reflects the emergence of non-Aspergillus infections (Table 1) , which are less susceptible to conventional antifungal drugs. 12 For example, infections due to the black moulds, especially Scedosporium prolificans, are resistant to most available antifungal agents, and disseminated infections due to Fusarium species, Pseudallescheria species, Scedosporium apiospermum and other dematiaceous molds have variable drug susceptibility profiles; owing to the high rates of failure with amphotericin B-based therapy, treatment of infections due to these non-Aspergillus molds is approached as salvage therapy, often with combinations of antifungal drugs. The unanticipated rise in zygomycoses, especially in patients receiving voriconazole prophylaxis, in the past few years 13 has been complicated by the fact that these infections are more serious leading to greater than 80% mortality in transplant recipients compared to other IFI.
Diagnosing IFI
Definite diagnosis of IFI requires histologic demonstration of tissue invasion by fungi and systemic signs of disease along with cultures and fungal identification. As obtaining tissue samples from most HSCT recipients is not feasible, the emphasis in these high-risk patients is placed on minimally invasive or non-invasive laboratory tests with better diagnostic yields than conventional culture-based methods. Furthermore, in severely immunosuppressed HSCT recipients, the isolation of saprophytic environmental molds from blood culture samples 14 or nonScedosporium species including S. apiospermum, and S. prolificans, from bronchoalveolar lavage specimens has been noted to have a low association with IFI. 15 The findings on non-contrast enhanced computed tomography chest scan are important in determining the empiric course of therapy for patients with a pulmonary processes. In Figure 1a , characteristic ground glass attenuation, the 'hypodense sign' or 'halo sign' in a patient with invasive aspergillosis is present in 480% of IFI within first 7 days of infection and is highly indicative of invasive fungal disease. 16, 17 Pleomorphic, irregular, multicentric and often peripheral, plural-based pulmonary nodules, espe- Fungal infection strategies after SCT A Safdar cially those presenting with thick-walled cavities are highly indicative pulmonary mycoses (Figure 1b) . Whereas, small lung nodules, o10 mm in diameters are more common in patients with viral infections and not likely to represent IFI. 18 The 'crescent sign' is a late finding and may be noted in patients following recovery of neutropenia. 19, 20 The current approach to the diagnosis of IFI after HACT includes: (1) an overall assessment of predisposing factors and determination of a patient's susceptibility to invasive mycosis, (2) fungal cultures from sterile body sites, (3) radiographic findings consistent with or suggestive of IFI, especially in the lungs and (4) the recently available enzyme immunoassays that detects fungal antigens (galactomannan (GM EIA) and D-glucan) or an investigational polymerase chain reaction (PCR) assay, which provides a measure of fungal tissue burden but is presently not available for clinical use. 21, 22 The overall diagnostic sensitivity of galactomannan assay in 27 studies between 1966 and 2005 was 71% and specificity was 89%; in patients with hematologic malignancies and HSCT recipients the results were more useful compared to patients with solid-organ cancer or solid-organ transplantation. The sensitivity and specificity of Aspergillus antigen immunoassays in these high-risk population are both nearly 90%; albeit in patients receiving mold-active drugs for prophylaxis or therapy, the sensitivity is markedly reduced ( Table 2) . 23 Furthermore, due to cross reactivity with piperacillin-tazobactam false positive GM EIA may complicate interpretation of these results and definite diagnostic tests such as PCR are sought. In recent reports, proven or probable invasive aspergillosis among patients with hematologic malignancy PCR analysis of whole blood (92% sensitivity, 95% vs specificity, 60% positive predictive value and 99% negative predictive value) 24 or serum samples (67% sensitivity, 88% specificity, 67% positive predictive value and 90% negative predictive value) 25 was promising; there was also 77% diagnostic concordance with GM EIA and high-resolution computed tomography scan. 24 
Responses to antifungal therapy
In allogeneic HSCT recipients with IFI, the rate of response to amphotericin B-based therapy is low, and despite treatment, the infection-associated mortality rate remains high. 26 Overall, the response to voriconazole as primary therapy for invasive aspergillosis is significantly better than that to amphotericin B; however, this therapeutic advantage is markedly reduced in patients with severe neutropenia after HSCT. 2 Salvage therapy with caspofungin has also led to modest improvement in IFI treatment responses, especially among the sub-group of patients who receive caspofungin owing to intolerance to the primary antifungal therapy rather than true treatment-refractory IFI. 3 Antifungal drug combinations appear to have additive and/or synergistic activity in experimental animal studies. In early clinical studies, caspofungin plus amphotericin B lipid preparation [27] [28] [29] and caspofungin plus voriconazole 27, 30 combinations were tolerated without serious adverse events and resulted in modest improvements in IFI response compared to single drug therapy in response, especially in severely immunosuppressed HSCT recipients. Increasing the caspofungin dose resulted in favorable survival 12 weeks after therapy compared with patients who were treated with standard dose caspofungin combination therapy. 31, 32 It is important to recognize that some drug combinations are antagonistic and thus may reduce therapeutic efficacy if used. Abelcet s , a less nephrotoxic amphotericin B lipid preparation, is suggested as the drug of choice for patients with invasive zygomycosis. Recent studies of posaconazole were encouraging, as nearly 50% of patients with zygomycoses responded to posaconazole alone. 33, 34 Posaconazole response in patients with other refractory non-Aspergillus species infections such as disseminated fusariosis also appears promising. 35 The roles of newer echinocandins, micafungin, and anidulafungin in the treatment of invasive mold infections have not been determined and need further study. Table 2 Diagnostic variability of galactomannan enzyme immunoassays (GM EIA) and impact of systemic antifungal drug exposure
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Antifungal immune responses
The host's innate immune response plays an important role in protection against invading fungal pathogens (Figure 2 ). The first line of defense includes acellular microbicidal components such as products of complement activation cascade, cationic proteins, and proteolytic enzyme secreted along the mucosal lining of the respiratory tract. The principle cellular component during this early non-antigen specific innate immune response is mediated via phagocytic activity of alveolar macrophages and recruited neutrophils; Toll-like receptor (TLR) 2 and TLR 4, were recently recognized as critical in the early recognition of infective Aspergillus conidia. 36, 37 Via a complex signaling cascade, these receptor leads to translocation of nuclear-factor-kB and induction of various proinflammatory cytokine genes and thus to improved effector cell immune function. Interestingly, TLR 4-mediated immune activation is more focused against the fungal microconidia; whereas, TLR 2 is important for eliciting immune response against microconidia and the developed fungal hyphae. 38 Tumor necrosis factor (TNF) has also been shown to be an essential mediator of early immune activation following ingestion of infectious fungal spores or microconidia. 39 TNF is also important in promoting selective early recruitment of leukocytes at the site of fungal invasion/infection. 40 Other important chemoattractants for neutrophil recruitment are the ELR-positive subset of CXC chemokines and corresponding CXCR2 receptors. 41 For the entry of mononuclear cells at the infection site, chemokine ligand 3 (CCL3)/macrophage inflammatory protein-1 alpha and CCL2/monocyte chemoattractant protein-1 are critical in Fungal infection strategies after SCT A Safdar the recruitment of monocytes and natural killer cells. 42 Other major chemokines that modulate early innate immunes response against filamentous mold infections include the macrophage-derived chemokines (CCL22), which enhance immune response among monocytes; DC; and natural killer cells. In contrast, the T H 2 driven thymus and activationregulated chemokines (CCL17) have immunosuppressive effects and impair the pulmonary antifungal innate immune response. 43 The T H 1 adaptive cellular immune response mediated via IL-12/IL-23, IL-18, IL-2 and IFN-g, the protagonist in this group, promotes the fungicidal activity of the host's mononuclear cells (Figure 2) . Moreover, dominance of T H 2 cytokines such as IL-4 and IL-10 abrogates the antifungal protection rendered by the T H 1-dependent antimycotic response. 44, 45 This defective T H 1 cytokine-mediated antifungal activity can be restored in experimental animals that have invasive aspergillosis by treatment with T H 2 cytokine inhibitors. 46 Interestingly, the host's cellular and humoral immune responses appear to be restricted to only the viable and germinating infectious fungal spores that carry a risk for invasive diseases; the mechanism by which the host's adaptive immune system differentiates between metabolically active and non-disease-causing inactive spores remains unknown. 47 Various pathways have been explored in selective recognition of germinating, infectious fungal microconidia, such as Dectin-1, and myeloid differentiation factor 88, these important regulatory molecules may be central in preventing indiscriminate activation of innate immune-inflammatory cytokine response against inhaled non-infectious environmental fungal spores. 48, 49 A number of factors adversely influence the host's antifungal immunity, including hematologic malignancy, antineoplastic chemotherapy, radiation therapy, HSCT, immunosuppressive agents given for the treatment of GVHD, including systemic corticosteroids. 1, 9, 50 Severe and prolonged chemotherapy-induced or cancer-related granulocytopenia is a well-known risk factor for IFI. 51 Among pathogen-associated factors that may adversely influence IFI include, gliotoxin, the most abundant mycotoxin produced by Aspergillus fumigatus, was recognized as an important virulence factor that suppresses the host's antifungal innate and cellular immune responses. A toxin-induced apoptosis of antigen-presenting cells is considered central for disease-causing fungi to evade host immune surveillance. 52 
Immune enhancement strategies
The infectious complications and immune dysfunction after HSCT varies in time of onset, duration, type and severity among patients undergoing myeloablative versus nonmyeloablative HSCT (Table 3) . It was interesting to note that frequency of infection and infection-associated death among recipients of non-myeloablative and myeloablative HSCT were comparable (16-77 and 7-88%, respectively). Furthermore, in patients undergoing either type of transplantation, higher infection rates occurred even in patients who had low rates of GVHD, which is considered as the most important predictor of IFI during late HSCT period.
The restoration of immune function is critical to effective treatment of IFI in these patients. Immune enhancement therapies include (1) mobilized donor granulocyte transfusion (GTX), (2) recombinant growth factors, (3) recombinant T H 1 cytokine therapy and (4) experimental modalities such as target-specific adaptive immune transfer.
Donor granulocyte transfusions
The severity and duration of granulocytopenia in cancer patients are two important predictors of the development of serious systemic bacterial and fungal infections. 53 Since the early 1960s, donor GTX have been used for infection prevention and/or treatment in patients with profound granulocytopenia. 54 The success of GTX depends on the dose of granulocytes transfused; however, large doses require sophisticated cell separation and leukocyte collection techniques and enhancement of the number of circulating granulocytes by pretreating the donor with recombinant growth factors and corticosteroids. [55] [56] [57] Donor priming with GM-CSF is desirable, although its use in healthy donors is limited owing to drug intolerance; in most institutions, G-CSF and dexamethasone are commonly used for this purpose. 58 In patients with a recent history of IFI, secondary GTX prophylaxis has had encouraging results. 58 However, whereas, GTX may help to prevent serious bacterial and fungal infections in patients with chemotherapy-induced severe neutropenia, the results in immunosuppressed cancer patients, have been variable. A recent meta-analysis of GTX for primary prevention of infection, the following three factors have been associated with significantly improved GTX efficacy: (a) an adequate granulocyte dose (45.0 Â 10 10 cells per transfusion), (b) donor/recipient leukocyte compatibility and (c) most important, a short duration (o2 weeks) of neutropenia, which was shown to reduce the risk of serious bacterial or fungal infection by nearly 80%. 59 The efficacy for adjuvant GTX in neutropenic patients with severe systemic bacterial or fungal infections treated between 1997 and 2005 was 50-82%. 49 Even in severely neutropenic patients with Candida species fungemia, despite the presence of multiple predictors of poor outcome including prolonged neutropenia, GTX were shown to improve short-term survival. 60 Immune enhancement with GTX Neutrophils, after migrating to the site of infection, engulf and kill fungi through the actions of proteolytic enzymes, antimicrobial proteins, and toxic oxygen radicals. Similar to recently described neutrophil extracellular traps (NET) composed of granules and nuclear structures that are effective in killing extracellular bacteria, these activated phagocytes may inundate and kill extracellular fungal pathogens without eliciting the severe inflammatory response that often occurs following non-NET indiscriminate release of oxygen radicals and other proteolytic enzymes. 61 In ex vivo models, granulocytes' intracellular and perhaps extracellular antimicrobial activity may be augmented via Represent infections that occur during the treatment course. c Fungal infections 3 12 out of 33 were fungal not specified by group. 8 One non-myeloablative and four myeloablative deaths due to fungal 9 represent only the fungal 12 one non-myeloablative and five myeloablative. Abbreviations: AML ¼ acute myelogenous leukemia; ALL ¼ acute lymphocytic leukemia; CLL ¼ chronic lymphocytic leukemia; CML ¼ chronic myelogenous leukemia; MDS ¼ myelodysplactic syndrome; MM ¼ myeloma multiple; NHL ¼ non-Hodgkin lymphoma; HL ¼ Hodgkin lymphoma; Flu ¼ fludarabine; Bu ¼ busulfan; rTBI ¼ reduce total body irradiation (2Gy); Cla ¼ cladribine; ATG ¼ antithymocyte globulin; TBI ¼ total body irradiation; Ida ¼ idarubicin; Cyta ¼ cytarabin; Cy ¼ cyclophosphamide; Ritu ¼ rituxan; Me ¼ melphalan; Thio ¼ thiothepa; Eto ¼ etoposide; TMI ¼ total marrow irradiation.
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recombinant growth factors and pro-inflammatory cytokines. 62 For this purpose, recombinant GM-CSF and recombinant IFN-g-1b (rIFN-g-1b) had been used in HSCT recipients with systemic infections; these cytokines were associated with no serious sequelae such as GVHD or relapsed cancer. 63, 64 We recently showed that adjuvant therapy with recombinant cytokines including GM-CSF and rIFN-g-1b in patients receiving donor GTX was well tolerated and possibly had a therapeutic benefit in patients with difficult-to-treat IFI. 65 Randomized, prospective trials are needed to further investigate strategies to improve the clinical efficacy of donor GTX.
Recombinant growth factors
Following allogeneic HSCT, the use of G-CSF has improved engraftment, graft survival, and overall survival among patients with poor graft function. 66 The use of G-CSF has also been successfully explored in the treatment of various systemic infections. 58 The therapeutic efficacy of G-CSF probably represents (1) increase in circulating neutrophils and (2) enhancement of the antimicrobial ability of neutrophils, especially by promoting killing of phagocytosed fungal microconidia via reactive oxygen species. It remains to be seen whether G-CSF and/or GM-CSF favorably influence the extracellular microbicidal activity by releasing antimicrobial factors into the extracellular medium or whether these immune modulators may promote and generate extracellular fibers or NET, 61 which may play an important role in killing non-phagocytosed invading filamentous molds. Another interesting mechanism by which GM-CSF may promote effective fungicidal activity is the induction of chitotriosidase, an important and highly regulated enzyme active against chitin (an integral component of fungal cell walls)-containing pathogens. 67, 68 GM-CSF also reverses steroid-induced dysfunction of alveolar and tissue macrophages' handing of the Aspergillus microconidia. 69, 70 Treatment with GM-CSF may enhance antifungal immune resistance in patients receiving systemic corticosteroids, especially in the setting of GVHD. Adjuvant treatment with G-CSF plus GM-CSF should be considered in select group of HSCT recipients with serious IFI, and even in non-neutropenic patients, especially those receiving treatment with systemic corticosteroids, GM-CSF 250-500 mg daily may be added to the antifungal regimen for the initial 2-3 weeks of therapy.
Recombinant T H 1 cytokines IFN-g-1b enhances the host's antimicrobial defense by promoting the intracellular microbicidal activity of effector mononuclear cells and polymorphonuclear phagocytes, which are critical in the defense against filamentous mold infections. 64, 65 Recombinant human IFN-g-1b (rhIFN-g1b) had been given safely in patients with IFI following allogeneic HSCT, with no serious adverse events, including no cytokine-related GVHD exacerbation; in fact, a number of patients with acute and chronic GVHD had measurable improvements following rhIFN-g-1b therapy. 64 Treatment with rhIFN-g-1b is currently regarded as salvage therapy for patients with refractory IFI that fails to respond to conventional therapy. However, I believe that the use of adjuvant immune modulators such as GM-CSF, rhIFN-g1b should be considered early in the course of IFI therapy, especially in the severely immunosuppressed recipients of allogeneic HSCT. Introducing these immune modulators late in the course of advanced fungal disease may not have a significant impact on infection outcome. However, recombinant IL-2 and IL-12 are associated with high rates of systemic toxicity and therefore, are not recommended for patients with IFI. Other T H 1 promoters such as IL-18 and IL-25 need further evaluation.
The recommended dose of rhIFN-g-1b in adults is 50 mg/m 2 of body surface area given every other day until complete clinical and radiographic resolution of the infection occurs. In patients with severe, multicentric or disseminated IFI, GM-CSF may be initially added with rhIFN-g-1b; however, because capillary leak syndrome may occur with GM-CSF, my preference is not to use GM-CSF for longer than 4-6 weeks.
Pentraxin. Pentraxin (PTX) is a highly conserved superfamily of proteins secreted by diverse cell types including mononuclear phagocytes, DC, and endothelial cells in response to pro-inflammatory signals such as TNF-a, IL-1 and selected microbial moieties. 71 PTX3 is an important component of the innate antimycotic immune response and acts by promoting complex effector pathways. Even in the unfavorable antifungal T H 2-predominant cytokine milieu, in animal experiments PTX3 facilitated macrophage antiAspergillus response and activated and improved DCmediated antifungal activity by acting as a non-redundant soluble target-specific 'pattern-recognition' receptor against pathogenic fungi.
71
Laboratory studies have been encouraging and show a potential therapeutic role of PTX3 in preventing fungal infections and a possible role as an adjuvant immuneenhancing agent in combination with antifungal drug therapy. 72 Additional evaluation is needed to elucidate the role of this novel agent and its potential applicability in clinical practice.
Adoptive cell transfer and DC vaccines. After HSCT and during treatment for GVHD, patients have a severely reduced ability to develop antigen-specific T cells. This deficit is often seen during the early post-transplant period owing to dysfunctional DC; in the later period, in patients with chronic GVHD, an inadequate T-cell response reflects a more complex immune defect involving disruption of several facets of immune activation. Adoptive transfer of Aspergillus (fungal species)-specific T cells is currently being explored as a treatment for IFI. Ex vivo-generation Aspergillus-specific donor T-cell clones have been successfully given to patients following HSCT; these target-specific T cells (CD3 þ /CD4 þ ) are long-lasting T H 1 (high IFN-g/ low IL-10) cells and in early trials did not lead to GVHD or compromise the stem cell graft. 73 Although the early results appear encouraging, the transfer of Aspergillus-specific T cells 74 may render patients susceptible to severe invasive disease due to other unrelated fungal species like Fusarium, or the dematiaceous (black) molds.
Following T-cell depleted HSCT, patients also have marked defects in the function of DC, cells critical in the initial stages of the adaptive cellular immune response against the inhaled infectious fungal microconidia. DC activated via pattern-recognition receptors such as Toll-like receptor 2, PTX3, are highly antigen specific and finely differentiate between conidia and Aspergillus hyphae, which in turn results in a specific adaptive immune response. The plasticity of these valuable cells in triggering a sustained antifungal response has been explored in the development of DC vaccines. In experimental models, DC stimulated ex vivo using live fungi or fungal nucleic acid resulted in the generation of local and systemic antigen-specific IFN-gproducing T cells. This desirable antifungal T H 1 response was also seen in animals following allogeneic SCT. 75 Various other methods of DC activation have been explored including RNA transfection, which may improve antifungal immune responses by enhancing protective T H 1 responses mediated by endogenous IL-12 and IL-18 and by enhancing IFN-g-mediated effector cell responses. The adoptive transfer of DC may also improve regulatory T-cell functions by promoting antigen-specific T-cell responses, which are severely inadequate in patients following T-cell depleted SCT. 76 Further clinical trials are needed to assess the clinical viability of this technology in HSCT patients at risk for IFI.
Conclusions
IFI are associated with significantly increased risk of infection-associated death especially in patients between ages 12-35 years, concurrent pleural effusion, low monocyte count (o120 cells/mm 3 ), systemic corticosteroids of 42 weeks within 2 months of IFI diagnosis, and uncontrolled GVHD. 77 Effective IFI therapy in this highrisk population poses a serious challenge on many fronts: (1) a rise in infections due to saprophytic molds with reduced drug susceptibility; (2) significantly reduced diagnostic efficacy of the new generation of enzymatic immunoassays in patients receiving systemic antifungal drugs; (3) it is difficult to reduce or eliminate predisposing factors in most patients with IFI; and (4) modest or no measurable increase in response to antifungal drug combinations compared with single drug therapy; furthermore potential drug-drug antagonism make selection of empiric-pre-emptive antimicrobial therapy for severely immunosuppressed HSCT recipients a daunting task. Improved understanding of the molecular pathogenesis of fungal infections and of the complexity of host antifungal immune responses has provided the critical information to readdress existing treatment paradigms and further evaluate the role of GM-CSF and IFN-g early in the course of therapy against life-threatening fungal infections in highrisk patients following stem cell transplantation.
